Vocalis Health COVID-19 Screening Tool Is Successfully Validated in Large Clinical Study

Companies in the Global Vaccine Delivery Devices Market Expedite Product Innovations to Stay at Forefront in the Market in the COVID-19 Pandemic

Fact.MR has recently compiled a report, which reveals that the vaccine delivery devices market globally is projected to reflect an impressive CAGR over the forecast period, 2017 – 2022.

Sirtex Medical and BlackSwan Vascular Report 1st Patient Enrolled in Pivotal LAVA Study

The LAVA Study, which stands for Liquid Embolization of Arterial Hemorrhages in Peripheral Vasculature, is a prospective, multicenter single-arm study of 113 subjects at 20 investigational sites in the U.S.

Cohen Children’s Medical Center: Covid-19 Teen Returns to Thank the Doctor Who Saved Her Life

It was nothing but bright sunshine at Cohen Children’s Medical Center when Karla Duarte, the first teenager in American to be treated for COVID-19 with extracorporeal membrane oxygenation (ECMO) stopped by to thank the medical team on the one-year anniversary of her discharge.

February 17, 2021

Vocalis Health notes the study included over 2,000 participants who spoke numerous languages including English, Hindi, Marathi, and Gujarati.

Results from an unblinded validation set of 288 participants demonstrated an AUC of 0.88, which translated to accuracy of 81.2 percent, sensitivity of 80.3 percent and specificity of 81.4 percent.

In addition to the results of this study, Vocalis Health today announced that its COVID-19 screening tool, VocalisCheck, has obtained a CE mark.  VocalisCheck is the first device with CE mark approval for its medical intended use of screening for COVID-19.

“PCR testing is being used to screen for COVID-19, which is an extremely expensive, resource-intensive, and time-consuming approach,” said Dr. Shady Hassan, Co-Founder, Chief Operating and Medical Officer of Vocalis Health. “Instead of misusing PCR testing for screening, utilizing a highly scalable screening tool like VocalisCheck can fill a significant gap in the current approach to COVID screening, with the ability to effectively funnel those with a high risk of infection to the appropriate diagnostic test.”

VocalisCheck has now proven its reliability to effectively identify COVID-19 risk in multiple studies, including this study in India, delivering reliable risk assessment for COVID-19 infection even in people who are not symptomatic.  In the study in India, a symptom checker alone correctly identified approximately 66 percent of the people with COVID-19 infection, while Vocalis Health’s COVID-19 vocal biomarker achieved >80 percent accuracy in assessing a person’s risk of COVID-19 infection.

“We are encouraged by the study’s findings, which further validate VocalisCheck’s ability to screen for COVID-19,” explained Tal Wenderow, CEO of Vocalis Health.  “These new results, combined with our recent CE-mark approval, demonstrate our commercial readiness to deploy the VocalisCheck screening tool to help businesses, governments, universities and others safely return to work, school, healthcare, and leisure while lightening the burden on health systems.”

 

spot_img

DON'T MISS

Related Articles